Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 9Phase NA 2Phase EARLY_PHASE1 2Phase 3 2Phase 1/2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Neoplasm Metastasis 8Colorectal Neoplasms 7Lung Neoplasms 6Prostatic Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Fallopian Tube Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Glioblastoma 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2

Interventions

Temozolomide 69Radiotherapy 30Bevacizumab 24Carboplatin 13pembrolizumab 12Radiation 11Carmustine 8Irinotecan 7temsirolimus 6Surgical Procedures, Operative 6Radiosurgery 6Erlotinib Hydrochloride 6atezolizumab 5Vorinostat 5Sirolimus 5Radiotherapy, Intensity-Modulated 5Nivolumab 5Lomustine 5Everolimus 5fludarabine 4Radiotherapy, Conformal 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Aminolevulinic Acid 4tipifarnib 3Sorafenib 3Paclitaxel 3IL13-PE38 3Granulocyte-Macrophage Colony-Stimulating Factor 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Glioblastoma × Specimen Handling × Clear all
NCT05432804 2026-05-18

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

National Cancer Institute (NCI)

Phase 1/2 Recruiting
97 enrolled
CNS

Glioblastoma

NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡